Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[203Pb]VMT-alpha-NET
- Development stage
- Phase 1
- Lead developer
- Perspective Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
[203Pb]VMT-alpha-NET is a diagnostic radiopharmaceutical that functions as a somatostatin receptor subtype 2 (SSTR2) antagonist. It consists of a modified somatostatin receptor-targeted peptide (VMT-α-NET) radiolabeled with lead-203 (203Pb), a gamma-emitting radioisotope. This agent is designed for SPECT/CT imaging of neuroendocrine tumors that express somatostatin receptors. It forms an ideal theranostic pair with [212Pb]VMT-alpha-NET, which is the therapeutic counterpart used for targeted alpha particle therapy. The VMT chelator efficiently binds both 203Pb and 212Pb, making it suitable for both imaging and therapy applications. [203Pb]VMT-alpha-NET is primarily used for dosimetry and treatment planning before administering the therapeutic [212Pb]VMT-alpha-NET.
- Other names
- 203Pb-VMT-alpha-NETLead-203 VMT-alpha-NETLead203 VMT-alpha-NETLead 203 VMT-alpha-NET
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on [203Pb]VMT-alpha-NET.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [203Pb]VMT-alpha-NET.